Intrinsic value of Cytokinetics - CYTK

Previous Close

$6.49

  Intrinsic Value

$12.85

stock screener

  Rating & Target

str. buy

+98%

Previous close

$6.49

 
Intrinsic value

$12.85

 
Up/down potential

+98%

 
Rating

str. buy

We calculate the intrinsic value of CYTK stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.4

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  21
  33
  49
  72
  101
  139
  187
  245
  315
  398
  495
  605
  729
  867
  1,020
  1,186
  1,367
  1,560
  1,767
  1,987
  2,219
  2,464
  2,720
  2,989
  3,269
  3,562
  3,867
  4,184
  4,513
  4,856
Variable operating expenses, $m
  18
  28
  42
  61
  86
  118
  158
  207
  267
  337
  419
  512
  617
  734
  863
  1,004
  1,156
  1,320
  1,495
  1,681
  1,877
  2,084
  2,301
  2,529
  2,766
  3,013
  3,271
  3,539
  3,818
  4,108
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  18
  28
  42
  61
  86
  118
  158
  207
  267
  337
  419
  512
  617
  734
  863
  1,004
  1,156
  1,320
  1,495
  1,681
  1,877
  2,084
  2,301
  2,529
  2,766
  3,013
  3,271
  3,539
  3,818
  4,108
Operating income, $m
  3
  5
  8
  11
  16
  21
  29
  38
  49
  61
  76
  93
  112
  134
  157
  183
  210
  240
  272
  306
  342
  379
  419
  460
  503
  549
  595
  644
  695
  748
EBITDA, $m
  4
  7
  10
  15
  21
  29
  39
  51
  66
  83
  104
  127
  153
  182
  214
  248
  286
  327
  370
  416
  465
  516
  570
  626
  685
  746
  810
  876
  945
  1,017
Interest expense (income), $m
  2
  3
  -7
  -2
  5
  13
  25
  40
  59
  82
  110
  143
  181
  224
  273
  328
  388
  454
  526
  602
  684
  771
  863
  959
  1,061
  1,167
  1,278
  1,394
  1,514
  1,640
  1,770
Earnings before tax, $m
  0
  12
  10
  7
  2
  -4
  -11
  -21
  -33
  -48
  -66
  -88
  -112
  -140
  -171
  -206
  -244
  -285
  -330
  -378
  -429
  -483
  -540
  -601
  -664
  -730
  -798
  -870
  -945
  -1,022
Tax expense, $m
  0
  3
  3
  2
  1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  0
  8
  7
  5
  2
  -4
  -11
  -21
  -33
  -48
  -66
  -88
  -112
  -140
  -171
  -206
  -244
  -285
  -330
  -378
  -429
  -483
  -540
  -601
  -664
  -730
  -798
  -870
  -945
  -1,022

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  96
  148
  222
  322
  454
  624
  837
  1,099
  1,414
  1,787
  2,219
  2,712
  3,269
  3,890
  4,574
  5,320
  6,129
  6,997
  7,925
  8,910
  9,951
  11,047
  12,198
  13,403
  14,661
  15,973
  17,339
  18,760
  20,238
  21,775
Adjusted assets (=assets-cash), $m
  96
  148
  222
  322
  454
  624
  837
  1,099
  1,414
  1,787
  2,219
  2,712
  3,269
  3,890
  4,574
  5,320
  6,129
  6,997
  7,925
  8,910
  9,951
  11,047
  12,198
  13,403
  14,661
  15,973
  17,339
  18,760
  20,238
  21,775
Revenue / Adjusted assets
  0.219
  0.223
  0.221
  0.224
  0.222
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
  0.223
Average production assets, $m
  6
  9
  14
  20
  28
  39
  52
  68
  87
  110
  137
  168
  202
  240
  283
  329
  379
  432
  490
  550
  615
  682
  753
  828
  906
  987
  1,071
  1,159
  1,250
  1,345
Working capital, $m
  -44
  -69
  -103
  -149
  -210
  -289
  -388
  -510
  -656
  -829
  -1,029
  -1,258
  -1,516
  -1,804
  -2,121
  -2,468
  -2,843
  -3,246
  -3,676
  -4,133
  -4,616
  -5,124
  -5,658
  -6,217
  -6,800
  -7,409
  -8,042
  -8,702
  -9,387
  -10,100
Total debt, $m
  -67
  -20
  46
  136
  255
  408
  600
  836
  1,120
  1,455
  1,843
  2,288
  2,789
  3,348
  3,963
  4,635
  5,363
  6,144
  6,979
  7,866
  8,803
  9,789
  10,825
  11,909
  13,041
  14,222
  15,452
  16,731
  18,061
  19,444
Total liabilities, $m
  86
  133
  199
  289
  408
  561
  753
  989
  1,273
  1,608
  1,997
  2,441
  2,942
  3,501
  4,116
  4,788
  5,516
  6,297
  7,132
  8,019
  8,956
  9,943
  10,978
  12,062
  13,195
  14,375
  15,605
  16,884
  18,214
  19,597
Total equity, $m
  10
  15
  22
  32
  45
  62
  84
  110
  141
  179
  222
  271
  327
  389
  457
  532
  613
  700
  792
  891
  995
  1,105
  1,220
  1,340
  1,466
  1,597
  1,734
  1,876
  2,024
  2,177
Total liabilities and equity, $m
  96
  148
  221
  321
  453
  623
  837
  1,099
  1,414
  1,787
  2,219
  2,712
  3,269
  3,890
  4,573
  5,320
  6,129
  6,997
  7,924
  8,910
  9,951
  11,048
  12,198
  13,402
  14,661
  15,972
  17,339
  18,760
  20,238
  21,774
Debt-to-equity ratio
  -6.970
  -1.340
  2.090
  4.240
  5.620
  6.540
  7.170
  7.610
  7.920
  8.140
  8.310
  8.440
  8.530
  8.610
  8.670
  8.710
  8.750
  8.780
  8.810
  8.830
  8.850
  8.860
  8.870
  8.890
  8.900
  8.900
  8.910
  8.920
  8.920
  8.930
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  0
  8
  7
  5
  2
  -4
  -11
  -21
  -33
  -48
  -66
  -88
  -112
  -140
  -171
  -206
  -244
  -285
  -330
  -378
  -429
  -483
  -540
  -601
  -664
  -730
  -798
  -870
  -945
  -1,022
Depreciation, amort., depletion, $m
  1
  2
  3
  4
  6
  8
  10
  14
  17
  22
  27
  34
  40
  48
  57
  66
  76
  86
  98
  110
  123
  136
  151
  166
  181
  197
  214
  232
  250
  269
Funds from operations, $m
  1
  10
  10
  9
  7
  4
  -1
  -7
  -16
  -26
  -39
  -54
  -72
  -92
  -114
  -140
  -168
  -199
  -232
  -268
  -306
  -347
  -390
  -435
  -482
  -532
  -584
  -638
  -695
  -753
Change in working capital, $m
  -17
  -24
  -34
  -46
  -61
  -79
  -99
  -122
  -146
  -173
  -200
  -229
  -258
  -288
  -317
  -346
  -375
  -403
  -430
  -457
  -483
  -509
  -534
  -559
  -584
  -609
  -634
  -659
  -686
  -713
Cash from operations, $m
  18
  35
  44
  55
  69
  83
  98
  114
  130
  146
  161
  175
  187
  196
  203
  206
  207
  204
  198
  189
  177
  162
  144
  124
  101
  76
  50
  21
  -9
  -41
Maintenance CAPEX, $m
  -1
  -1
  -2
  -3
  -4
  -6
  -8
  -10
  -14
  -17
  -22
  -27
  -34
  -40
  -48
  -57
  -66
  -76
  -86
  -98
  -110
  -123
  -136
  -151
  -166
  -181
  -197
  -214
  -232
  -250
New CAPEX, $m
  -2
  -3
  -5
  -6
  -8
  -11
  -13
  -16
  -19
  -23
  -27
  -31
  -34
  -38
  -42
  -46
  -50
  -54
  -57
  -61
  -64
  -68
  -71
  -74
  -78
  -81
  -84
  -88
  -91
  -95
Cash from investing activities, $m
  -3
  -4
  -7
  -9
  -12
  -17
  -21
  -26
  -33
  -40
  -49
  -58
  -68
  -78
  -90
  -103
  -116
  -130
  -143
  -159
  -174
  -191
  -207
  -225
  -244
  -262
  -281
  -302
  -323
  -345
Free cash flow, $m
  15
  30
  37
  46
  56
  67
  77
  88
  97
  106
  113
  117
  119
  117
  112
  104
  91
  75
  54
  30
  2
  -29
  -64
  -101
  -142
  -186
  -232
  -281
  -332
  -386
Issuance/(repayment) of debt, $m
  -99
  47
  66
  90
  119
  153
  192
  236
  284
  335
  389
  444
  501
  558
  616
  672
  727
  782
  835
  887
  937
  987
  1,036
  1,084
  1,132
  1,181
  1,230
  1,279
  1,330
  1,383
Issuance/(repurchase) of shares, $m
  136
  0
  0
  5
  12
  21
  33
  47
  65
  86
  110
  137
  168
  202
  239
  280
  325
  372
  423
  476
  533
  593
  656
  721
  789
  861
  935
  1,012
  1,092
  1,176
Cash from financing (excl. dividends), $m  
  37
  47
  66
  95
  131
  174
  225
  283
  349
  421
  499
  581
  669
  760
  855
  952
  1,052
  1,154
  1,258
  1,363
  1,470
  1,580
  1,692
  1,805
  1,921
  2,042
  2,165
  2,291
  2,422
  2,559
Total cash flow (excl. dividends), $m
  53
  77
  104
  141
  187
  240
  302
  371
  446
  526
  611
  698
  788
  878
  967
  1,056
  1,143
  1,229
  1,312
  1,393
  1,473
  1,551
  1,628
  1,704
  1,780
  1,856
  1,932
  2,011
  2,091
  2,173
Retained Cash Flow (-), $m
  -136
  -5
  -7
  -10
  -13
  -21
  -33
  -47
  -65
  -86
  -110
  -137
  -168
  -202
  -239
  -280
  -325
  -372
  -423
  -476
  -533
  -593
  -656
  -721
  -789
  -861
  -935
  -1,012
  -1,092
  -1,176
Prev. year cash balance distribution, $m
  236
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  153
  72
  97
  131
  174
  220
  269
  323
  381
  441
  501
  562
  620
  676
  728
  776
  819
  856
  889
  917
  940
  958
  972
  983
  990
  995
  997
  998
  998
  997
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  146
  66
  84
  108
  135
  160
  182
  202
  219
  231
  238
  240
  236
  227
  214
  197
  178
  158
  137
  116
  97
  79
  64
  50
  39
  29
  21
  15
  11
  8
Current shareholders' claim on cash, %
  50.0
  50.0
  49.6
  46.2
  41.5
  36.4
  31.3
  26.6
  22.4
  18.9
  15.8
  13.3
  11.1
  9.3
  7.8
  6.6
  5.5
  4.6
  3.9
  3.3
  2.8
  2.3
  2.0
  1.7
  1.4
  1.2
  1.0
  0.8
  0.7
  0.6

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.

FINANCIAL RATIOS  of  Cytokinetics (CYTK)

Valuation Ratios
P/E Ratio 16.5
Price to Sales 2.5
Price to Book 2.8
Price to Tangible Book
Price to Cash Flow 7.1
Price to Free Cash Flow 7.5
Growth Rates
Sales Growth Rate 265.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 100%
Cap. Spend. - 3 Yr. Gr. Rate 14.9%
Financial Strength
Quick Ratio 52
Current Ratio 0
LT Debt to Equity 28.7%
Total Debt to Equity 31.9%
Interest Coverage 9
Management Effectiveness
Return On Assets 12.6%
Ret/ On Assets - 3 Yr. Avg. -10.6%
Return On Total Capital 15.4%
Ret/ On T. Cap. - 3 Yr. Avg. -16.1%
Return On Equity 19.6%
Return On Equity - 3 Yr. Avg. -16%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 17.9%
EBITDA Margin - 3 Yr. Avg. -47.2%
Operating Margin 17%
Oper. Margin - 3 Yr. Avg. -47.5%
Pre-Tax Margin 15.1%
Pre-Tax Margin - 3 Yr. Avg. -49.3%
Net Profit Margin 15.1%
Net Profit Margin - 3 Yr. Avg. -49.3%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

CYTK stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CYTK stock intrinsic value calculation we used $13.368 million for the last fiscal year's total revenue generated by Cytokinetics. The default revenue input number comes from 0001 income statement of Cytokinetics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CYTK stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for CYTK is calculated based on our internal credit rating of Cytokinetics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Cytokinetics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CYTK stock the variable cost ratio is equal to 84.6%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for CYTK stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 9.8% for Cytokinetics.

Corporate tax rate of 27% is the nominal tax rate for Cytokinetics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CYTK stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CYTK are equal to 27.7%.

Life of production assets of 1.9 years is the average useful life of capital assets used in Cytokinetics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CYTK is equal to -208%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $109.842 million for Cytokinetics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 54.198 million for Cytokinetics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Cytokinetics at the current share price and the inputted number of shares is $0.4 billion.

RELATED COMPANIES Price Int.Val. Rating
AMGN Amgen 192.45 130.16  sell
VYGR Voyager Therap 12.18 1.30  str.sell
BIIB Biogen 321.72 402.94  hold
ACOR Acorda Therape 18.97 16.91  sell
IONS Ionis Pharmace 51.67 6.10  str.sell
PTCT PTC Therapeuti 33.26 214.00  str.buy
CUR Neuralstem 0.540 0.13  str.sell

COMPANY NEWS

▶ Cytokinetics: 3Q Earnings Snapshot   [04:08PM  Associated Press]
▶ Cytokinetics to Host R&D Day on October 16, 2018   [Oct-02-18 04:00PM  GlobeNewswire]
▶ Cantor Fitzgerald's 7 Buys For 7 Biotechs   [Sep-21-18 03:32PM  Benzinga]
▶ Cytokinetics Downgraded On Data Delay   [Aug-01-18 09:39AM  Benzinga]
▶ Cytokinetics: 2Q Earnings Snapshot   [Jul-26-18 05:19PM  Associated Press]
▶ 3 Biotechs with Upcoming Data to Watch   [Jun-11-18 10:34AM  SmarterAnalyst]
▶ June Best Growth Stocks   [Jun-05-18 12:02PM  Simply Wall St.]
▶ Cytokinetics to Hold Annual Meeting of Stockholders   [May-10-18 04:00PM  GlobeNewswire]
▶ Cytokinetics: 1Q Earnings Snapshot   [Apr-27-18 05:06AM  Associated Press]
▶ Cytokinetics to Present at March Investor Conferences   [Mar-05-18 04:00PM  GlobeNewswire]
▶ Cytokinetics reports 4Q loss   [Feb-15-18 04:34PM  Associated Press]
▶ Cytokinetics Earnings Outlook   [09:29AM  Benzinga]
▶ Cytokinetics Announces Progress Against Vision 2020   [Jan-03-18 07:30AM  GlobeNewswire]
▶ Cytokinetics Crumbles on Late-Stage Results   [11:04AM  24/7 Wall St.]
▶ Why Is Cytokinetics Plunging Today?   [09:47AM  Benzinga]
▶ Is It Too Late To Buy Cytokinetics Incorporated (CYTK)?   [Nov-14-17 09:09AM  Simply Wall St.]
▶ Cytokinetics reports 3Q loss   [Oct-26-17 05:47PM  Associated Press]
▶ Cytokinetics to Present at September Investor Conferences   [Sep-05-17 04:00PM  GlobeNewswire]
▶ Cytokinetics reports 2Q loss   [Aug-02-17 10:34PM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.